Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
03 Oct 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2022 | Download |
29 Jul 2022 | Other relevant información | On 26 July 2022 the public deed relating to the Company’s share capital decrease was registered with the Commercial Registry of Madrid. | Download |
27 Jul 2022 | On business and financial situation | The Company releases the press release related to the first half 2022 financial results | Download |
27 Jul 2022 | On business and financial situation | The Company releases the first half 2022 financial results presentation | Download |
04 Jul 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2022 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
21 Feb 2012 | Información sobre resultados (2) | Download | |
21 Feb 2012 | Información sobre resultados | Download | |
21 Feb 2012 | Informe Anual de Gobierno Corporativo | Download | |
15 Feb 2012 | Cambios en política de inversión, áreas de negocio y líneas de productos | Download | |
22 Dec 2011 | Composición del Consejo de Administración | Download |